MedTrace Logo

COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)

NCT04367402 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2020-04-30

No results posted yet for this study

Summary

The aims of this study is to define the genetic bases of COVID-19 related disease heterogeneity in frail population, to carry out a retrospective study on individuals w/wo symptoms to verify the reliability of a prognostic/diagnostic test based on IgM/IgG analysis and on the presence of genetic profiling and to explore the therapeutic potential of the modulation of ACE2 expression.

Conditions

Interventions

OTHER

BioMedomics COVID-19 IgM-IgG Rapid Test

Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus

Sponsors & Collaborators

  • Azienda Ospedaliera San Paolo

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-30
Primary Completion
2020-04-24
Completion
2020-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04367402 on ClinicalTrials.gov